Moderna Inc. (NASDAQ: MRNA) continued to face significant pressure in 2026 as the company’s post-COVID transition to new vaccine and therapeutic applications has progressed more slowly than investors had hoped.
The stock had been present in broader NASDAQ watchlists on Friday, May 22, with trading activity reflecting the uncertain near-term outlook for the company’s pipeline.
Moderna’s mRNA technology platform remains one of the most closely watched in biotechnology, with the company pursuing applications in flu, RSV, cancer vaccines, and rare disease therapeutics.
The company’s COVID-19 vaccine revenue has declined sharply from pandemic-era peaks, and investors are now focused on whether Moderna can replace that revenue with new products at sufficient scale.
Pipeline readouts from Moderna’s personalised cancer vaccine programme, developed in partnership with Merck, are expected to be among the most significant biotech catalysts of 2026.
The personalised mRNA cancer vaccine combines Moderna’s platform with Merck’s Keytruda immunotherapy and has shown promising early results in skin cancer and other tumour types.
Analysts remain divided on MRNA, with bulls citing the transformative potential of the mRNA platform and bears questioning whether the commercial ramp will come quickly enough to justify the current valuation.
Moderna has been managing costs aggressively through 2025 and 2026, cutting headcount and reducing research expenditure to preserve cash while key pipeline programmes advance.
The company holds a substantial cash position, giving it runway to fund its pipeline through the critical late-stage clinical readouts expected in the next 12 to 18 months.
Investor sentiment on MRNA remains cautious, and the stock will likely remain volatile until the company can demonstrate a clear and credible path to sustainable revenue beyond COVID vaccines.
